p53-Independent Functions of MDM2

Molecular Cancer Research

Volumn 1, Issue 14, 2003, Pages 1027-1035

  Ganguli, Gitali ^a   Wasylyk, Bohdan ^a,b  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARF PROTEIN; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; BINDING PROTEIN; DNA; DNA DIRECTED DNA POLYMERASE EPSILON; DNA POLYMERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P300; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; CANCER CELL CULTURE; CANCER MODEL; CELL CYCLE; CELL DIFFERENTIATION; CELL FATE; DNA REPAIR; DNA SYNTHESIS; GENETIC TRANSCRIPTION; HUMAN; IN VIVO STUDY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; RIBOSOME; TUMOR; WILD TYPE;

ANIMALS; CELL CYCLE; CELL DEATH; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 0345824731     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994.
2. Lu, M. L., Wikman, F., Omtoft, T. F., Charytonowicz, E., Rabbani, F., Zhang, Z., Dalbagni, G., Pohar, K. S., Yu, G., and Cordon-Cardo, C. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin. Cancer Res., 8: 171-179, 2002.
3. Bartel, F., Taubert, H., and Harris, L. C. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell, 2: 9-15, 2002.
4. Faustino, N. A. and Cooper, T. A. Pre-mRNA splicing and human disease. Genes Dev., 17: 419-437, 2003.
5. Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., and Finlay, C. A. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev., 11: 714-725, 1997.
6. Reinke, V., Bortner, D. M., Amelse, L. L., Lundgren, K., Rosenberg, M. P., Finlay, C. A., and Lozano, G. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth & Differ., 10: 147-154, 1999.
7. Jones, S. N., Hancock, A. R., Vogel, H., Donehower, L. A., and Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA, 95: 15608-15612, 1998.
8. Alkhalaf, M., Ganguli, G., Messaddeq, N., Le Meur, M., and Wasylyk, B. MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice. Oncogene, 18: 1419-1434, 1999.
9. Ganguli, G., Abecassis, J., and Wasylyk, B. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO J., 19: 5135-5147, 2000.
10. Dazard, J. E., Augias, D., Neel, H., Mils, V., Marechal, V., Basset-Seguin, N., and Piette, J. MDM-2 protein is expressed in different layers of normal human skin. Oncogene, 14: 1123-1128, 1997.
11. Fiddler, T. A., Smith, L., Tapscott, S. J., and Thayer, M. J. Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol. Cell. Biol., 16: 5048-5057, 1996.
12. Almog, N. and Rotter, V. Involvement of p53 in cell differentiation and development. Biochim. Biophys. Acta, 1333: F1-F27, 1997.
13. Mills, A. A., Zheng, B., Wang, X. J., Vogel, H., Roop, D. R., and Bradley, A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature, 398: 708-713, 1999.
14. Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C., and McKeon, F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature, 398: 714-718, 1999.
15. Parsa, R., Yang, A., McKeon, F., and Green, H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J. Invest. Dermatol., 113: 1099-1105, 1999.
16. Weinberg, W. C., Azzoli, C. G., Chapman, K., Levine, A. J., and Yuspa, S. H. p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene, 10: 2271-2279, 1995.
17. Hall, P. A., McKee, P. H., Menage, H. D., Dover, R., and Lane, D. P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene, 8: 203-207, 1993.
18. Leveitlard, T., Gorry, P., Niederreither, K., and Wasylyk, B. MDM2 expression during mouse embryogenesis and the requirement of p53. Mech. Dev., 74: 189-193, 1998.
19. Freedman, D. A. and Levine, A. J. Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res., 59: 1-7, 1999.
20. Haines, D. S. The mdm2 proto-oncogene. Leuk. Lymphoma, 26: 227-238, 1997.
21. Juven-Gershon, T. and Oren, M. Mdm2: the ups and downs. Mol. Med., 5: 71-83, 1999.
22. Momand, J., Wu, H. H., and Dasgupta, G. MDM2 - master regulator of the p53 tumor suppressor protein. Gene, 242: 15-29, 2000.
23. Piette, J., Neel, H., and Marechal, V. Mdm2: keeping p53 under control. Oncogene, 15: 1001-1010, 1997.
24. Prives, C. Signaling to p53: breaking the MDM2-p53 circuit. Cell, 95: 5-8, 1998.
25. Tron, V. A., Trotter, M. J., Tang, L., Krajewska, M., Reed, J. C., Ho, V. C., and Li, G. p53-regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. Am. J. Pathol., 153: 579-585, 1998.
26. Tron, V. A., Trotter, M. J., Ishikawa, T., Ho, V. C., and Li, G. p53-dependent regulation of nucleotide excision repair in murine epidermis in vivo. J. Cutan. Med. Surg., 3: 16-20, 1998.
27. Song, S. and Lambert, P. F. Different responses of epidermal and hair follicular cells to radiation correlate with distinct patterns of p53 and p21 induction. Am. J. Pathol., 155: 1121-1127, 1999.
28. Dubs-Poterszman, M. C., Tocque, B., and Wasylyk, B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene, 11: 2445-2449, 1995.
29. Adams, P. D. and Kaelin, W. G., Jr. Transcriptional control by E2F. Semin. Cancer Biol., 6: 99-108, 1995.
30. Guo, C. S., Degnin, C., Fiddler, T. A., Stauffer, D., and Thayer, M. J. Regulation of MyoD activity and muscle cell differentiation by MDM2, pRb, and Spl. J. Biol. Chem., 278: 22615-22622, 2003.
31. Brown, D. R., Thomas, C. A., and Deb, S. P. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J., 17: 2513-2525, 1998.
32. Deb, S. P. Cell Cycle Regulatory Functions of the Human Oncoprotein MDM2. Mol. Cancer Res., 1: 1009-1016.
33. Xiao, Z. X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R., and Livingston, D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature, 375: 694-698, 1995.
34. Hsieh, J. K., Chan, F. S., O'Connor, D. J., Mittnacht, S., Zhong, S., and Lu, X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell, 3: 181-193, 1999.
35. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B., and Kouzarides, T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature, 375: 691-694, 1995.
36. Loughran, O. and La Thangue, N. B. Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol. Cell. Biol., 20: 2186-2197, 2000.
37. Kowalik, T. F., DeGregori, J., Leone, G., Jakoi, L., and Nevins, J. R. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth & Differ., 9: 113-118, 1998.
38. Blattner, C., Sparks, A., and Lane, D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol., 19: 3704-3713, 1999.
39. Wunderlich, M. and Berberich, S. J. Mdm2 inhibition of p53 induces E2F1 transactivation via p21. Oncogene, 21: 4414-4421, 2002.
40. Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., and Jochemsen, A. G. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J., 15: 5349-5357, 1996.
41. Shvarts, A., Bazuine, M., Dekker, P., Ramos, Y. F., Steegenga, W. T., Merckx, G., van Ham, R. C., van der Houven van Oordt, W., van der Eb, A. J., and Jochemsen, A. G. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics, 43: 34-42, 1997.
42. Finch, R. A., Donoviel, D. B., Potter, D., Shi, M., Fan, A., Freed, D. D., Wang, C. Y., Zambrowicz, B. P., Ramirez-Solis, R., Sands, A. T., and Zhang, N. mdmx is a negative regulator of p53 activity in vivo. Cancer Res., 62: 3221-3225, 2002.
43. Migliorini, D., Denchi, E. L., Danovi, D., Jochcmsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P. G., and Marine, J. C. Mdm4 (Mdmx) rcgulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol., 22: 5527-5538, 2002.
44. Wei, X., Yu, Z. K., Ramalingam, A., Grossman, S. R., Yu, J. H., Bloch, D. B., and Maki, C. G. Physical and functional interactions between PML and MDM2. J. Biol. Chem., 278: 29288-29297, 2003.
45. Boyd, M. T., Vlatkovic, N., and Haines, D. S. A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J. Biol. Chem., 275: 31883-31890, 2000.
46. Sun, P., Dong, P., Dai, K., Hannon, G. J., and Beach, D. p53-independent role of MDM2 in TGF-β1 resistance. Science, 282: 2270-2272, 1998.
47. Blain, S. W. and Massague, J. Differcnt sensitivity of the transforming growth factor-β cell cycle arrest pathway to c-Myc and MDM-2. J. Biol. Chem., 275: 32066-32070, 2000.
48. Juven-Gershon, T., Shifman, O., Unger, T., Elkeles, A., Haupt, Y., and Oren, M. The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol. Cell. Biol., 18: 3974-3982, 1998.
49. Yogosawa, S., Miyauchi, Y., Honda, R., Tanaka, H., and Yasuda, H. Mammalian Numb is a target protein of Mdm2, ubiquitin ligase. Biochem. Biophys. Res. Commun., 302: 869-872, 2003.
50. Vlatkovic, N., Guerrera, S., Li, Y., Linn, S., Haines, D. S., and Boyd, M. T. MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase ε. Nucleic Acids Res., 28: 3581-3586, 2000.
51. Asahara, H., Li, Y., Fuss, J., Haines, D. S., Vlatkovic, N., Boyd, M. T., and Linn, S. Stimulation of human DNA polymerase ε by MDM2. Nucleic Acids Res., 31: 2451-2459, 2003.
52. Elenbaas, B., Dobbelstein, M., Roth, J., Shenk, T., and Levine, A. J. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med., 2: 439-451, 1996.
53. Marechal, V., Elenbaas, B., Piette, J., Nicolas, J. C., and Levine, A. J. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell. Biol., 14: 7414-7420, 1994.
54. Marechal, V., Elenbaas, B., Taneyhill, L., Piette, J., Mechali, M., Nicolas, J. C., Levine, A. J., and Moreau, J. Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis. Oncogene, 14: 1427-1433, 1997.
55. Lohrum, M. A., Ashcroft, M., Kubbutat, M. H., and Vousden, K. H. Identification of a cryptic nucleolar-localization signal in MDM2. Nat. Cell Biol., 2: 179-181, 2000.
56. Burley, S. K. The TATA box binding protein. Curr. Opin. Struct. Biol., 6: 69-75, 1996.
57. Colgan, J., Wampler, S., and Manley, J. L. Interaction between a transcriptional activator and transcription factor IIB in vivo. Nature, 362: 549-553, 1993.
58. Leng, P., Brown, D. R., Shivakumar, C. V., Deb, S., and Deb, S. P. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene, 10: 1275-1282, 1995.
59. Roberts, S. G., Ha, I., Maldonado, E., Reinberg, D., and Green, M. R. Interaction between an acidie activator and transcription factor TFIIB is required for transcriptional activation. Nature, 363: 741-744, 1993.
60. Leveillard, T. and Wasylyk, B. The MDM2 C-terminal region binds to TAF11250 and is required for MDM2 regulation of the cyclin A promoter. J. Biol. Chem., 272: 30651-30661, 1997.
61. Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z. X., Kumar, S., Howley, P. M., and Livingston, D. M. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell, 2: 405-415, 1998.
62. Thomas, A. and White, E. Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function. Genes Dev., 12: 1975-1985, 1998.
63. Wasylyk, C. and Wasylyk, B. Defect in the p53-Mdm2 autoregulatory loop resulting from inactivation of TAF(II)250 in cell cycle mutant tsBN462 cells. Mol. Cell. Biol., 20: 5554-5570, 2000.
64. Zeng, S. X., Jin, Y., Kuninger, D. T., Rotwein, P., and Lu, H. The acetylase activity of p300 is dispensable for MDM2 stabilization. J. Biol. Chem., 278: 7453-7458, 2003.
65. Gu, L., Findley, H. W., and Zhou, M. MDM2 induces NF-κB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood, 99: 3367-3375, 2002.
66. Shenoy, S. K., McDonald, P. H., Kohout, T. A., and Lefkowitz, R. J. Regulation of receptor fate by ubiquitination of activated β2-adrenergic receptor and β-arrestin. Science, 294: 1307-1313, 2001.
67. Strous, G. J. and Schantl, J. A. β-Arrestin and Mdm2, unsuspected partners in signaling from the cell surface. Sci. STKE, 110: PE41, 2001.
68. Chin, L., Pomerantz, J., and DePinho, R. A. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem. Sci., 23: 291-296, 1998.
69. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA, 95: 8292-8297, 1998.
70. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H. W., Cordon-Cardo, C., and DePinho, R. A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
71. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a focus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
72. Tao, W. and Levine, A. J. P19(ARF) stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA, 96: 6937-6941, 1999.
73. Zhang, R. and Wang, H. MDM2 oncogene as a novel target for human cancer therapy. Curr. Pharm. Des., 6: 393-416, 2000.
74. Foster, C. J. and Lozano, G. Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene, 21: 3525-3531, 2002.
75. Ruland, J., Sirard, C., Elia, A., MacPherson, D., Wakeham, A., Li, L., de la Pompa, J. L., Cohen, S. N., and Mak, T. W. p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. Proc. Natl. Acad. Sci. USA, 98: 1859-1864, 2001.
76. Li, L., Liao, J., Ruland, J., Mak, T. W., and Cohen, S. N. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc. Natl. Acad. Sci. USA, 98: 1619-1624, 2001.
77. Rics, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., and McCormick, F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell, 103: 321-330, 2000.
78. Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., and Vousden, K. H. p14ARF links the tumour suppressors RB and p53 [letter]. Nature, 395: 124-125, 1998.
79. Shaulian, E., Resnitzky, D., Shifman, O., Blandino, G., Amsterdam, A., Yayon, A., and Oren, M. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene, 15: 2717-2725, 1997.
80. Phelps, M., Darley, M., Primrose, J. N., and Blaydes, J. P. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor α-positive breast cancer cells. Cancer Res., 63: 2616-2623, 2003.
81. Mayo, L. D. and Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA, 98: 11598-11603, 2001.
82. Mayo, L. D. and Donner, D. B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci., 27: 462-467, 2002.
83. Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and Hung, M. C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol., 3: 973-982, 2001.
84. Sengupta, S. and Wasylyk, B. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes Dev., 15: 2367-2380, 2001.
85. Wang, H., Nan, L., Yu, D., Agrawal, S., and Zhang, R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res., 7: 3613-3624, 2001.